Increasing Coronavirus cases in India
The Central government on Thursday announced that Bharat Biotech’s indigenously developed COVAXIN has been moved out of the “clinical trial mode” and now COVAXIN has been granted the restricted emergency use authorization. The Dr.V K Paul who is the member (Health) NITI Aayog said that COVAXIN has been granted permission for restricted use in emergency situations in the public interest and both COVID-19 vaccines Bharat Biotech’s COVAXIN and COVISHIELD which manufactured by Serum Institute of India (SII) have the same licensure status now.
“The condition of it (Covaxin) being required to be administered under clinical trial mode is no more there,” said Dr.VK Paul
“Both the COVID-19 vaccines Covaxin and Covishield have the same licensure status. Covaxin has stood the test of time in terms of great safety. Only 311 individuals have minimal side effects. It is the triumph for India’s research and development enterprise and Science and technology enterprise.” Dr.Paul added
Also Read : Breaking- India reports 23,285 new COVID-19 case-https://www.medicallyspeaking.in/covid-news-updates/breaking-india-reports-23285-new-covid-19-cases/
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…